Meeting Transfusion Safety Expectations
Authors: James P. AuBuchon
Journal: Annals of Internal Medicine (2005)

Editorials4 October 2005Meeting Transfusion Safety ExpectationsJames P. AuBuchon, MDJames P. AuBuchon, MDFrom Dartmouth-Hitchcock Medical Center, Lebanon, NH 03782.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-7-200510040-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The problem with success is that you've succeeded.—Woody AllenThe public has high expectations for health care services, and this is certainly evident in its attention to virologic transmission risks in the blood supply. The focus of blood collectors, test manufacturers, and regulators on reducing the risk for transmission of HIV and hepatitis C virus (HCV) has resulted in dramatic reductions in these risks during the past 2 decades. However, linear continuation of this effort will result in inadequate attention being paid to problems that have greater impacts on transfusion recipients' morbidity and mortality and missed opportunities for substantial improvements ...References1. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254-64. [PMID: 15660836] CrossrefMedlineGoogle Scholar2. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-9. [PMID: 12385406] CrossrefMedlineGoogle Scholar3. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721-9. [PMID: 12757522] CrossrefMedlineGoogle Scholar4. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004;86:28-40. [PMID: 14984557] CrossrefMedlineGoogle Scholar5. Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, et al. The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion. 2005;45:469-79. [PMID: 15819665] CrossrefMedlineGoogle Scholar6. Food and Drug Administration. Guidance for Industry: Assessing donor suitability and blood and blood product safety in cases of known or suspected West Nile virus infection. Accessed at www.fda.gov/cber/gdlns/wnvguid.htm on 27 July 2005. Google Scholar7. Stramer SL, Brodsky JP, Foster GA, Paolillo JE, Wagner AG, Bremer R, et al. Yield of WNV RNA screening of US blood donors: yield of minipool vs individual donation NAT [Abstract]. Transfusion. 2004;44 Suppl 2A. Google Scholar8. Custer B, Busch MP, Marfin AA, Petersen LR. The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med. 2005;143:486-92. LinkGoogle Scholar9. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33:721-6. [PMID: 15818095] CrossrefMedlineGoogle Scholar10. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA, et al. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev. 2005;19:2-31. [PMID: 15830325] CrossrefMedlineGoogle Scholar11. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion. 1992;32:601-6. [PMID: 1519323] CrossrefMedlineGoogle Scholar12. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583-90. [PMID: 2402771] CrossrefMedlineGoogle Scholar13. Linden JV, Tourault MA, Scribner CL. Decrease in frequency of transfusion fatalities [Letter]. Transfusion. 1997;37:243-4. [PMID: 9051106] CrossrefMedlineGoogle Scholar14. Wenz B, Mercuriali F, AuBuchon JP. Practical methods to improve transfusion safety by using novel blood unit and patient identification systems. Am J Clin Pathol. 1997;107 suppl 4 S12-6. [PMID: 9124223 ] MedlineGoogle Scholar15. Marconi M, Langeberg AF, Sirchia G, Sandler SG. Improving transfusion safety by electronic identification of patients, blood samples, and blood units. Immunohematol. 2000;16:82-5. [PMID: 15373624] CrossrefMedlineGoogle Scholar16. Silva MA, Gregory KR, Carr-Greer MA, Holmberg JA, Kuehnert MJ, Brecher ME. Summary of the AABB Interorganizational Task Force on Bacterial Contamination of Platelets. Fall 2004 Impact Survey. Transfusion [In press]. Google Scholar17. Fatal bacterial infections associated with platelet transfusions—United States, 2004. MMWR Morb Mortal Wkly Rep. 2005;54:168-70. [PMID: 15729217] MedlineGoogle Scholar18. Zuck TF. Greetings—a final look back with comments about a policy of a zero-risk blood supply [Editorial]. Transfusion. 1987;27:447-8. [PMID: 3686652] CrossrefMedlineGoogle Scholar19. Dzik WH. Emily Cooley Lecture 2002: transfusion safety in the hospital. Transfusion. 2003;43:1190-9. [PMID: 12919420] CrossrefMedlineGoogle Scholar20. AuBuchon JP. Emily Cooley Memorial Award. Managing change to improve transfusion safety. Transfusion. 2004;44:1377-83. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Dartmouth-Hitchcock Medical Center, Lebanon, NH 03782.Disclosures: Consultancies: Baxter Healthcare, Cerus, Chiron Corp., Gambro, BCT, Immunetics, Navigant Biotechnologies, Pall Medical, Verax Biomedical, ZymeQuest; Grants received: Baxter Healthcare, Gambro BCT, Haemonetics, Immunetics, Navigant Biotechnologies, Pall Medical, Terumo, Verax Biomedical, ZymeQuest.Current Author Address: James P. AuBuchon, MD, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03782; e-mail, james.p.[email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Cost-Effectiveness of Screening the U.S. Blood Supply for West Nile Virus Brian Custer , Michael P. Busch , Anthony A. Marfin , and Lyle R. Petersen Correction: Meeting Transfusion Safety Expectations Metrics Cited byThrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasmaOverview of the Flaviviridae With an Emphasis on the Japanese Encephalitis Group VirusesAnaplasma phagocytophilum Transmitted Through Blood Transfusion—Minnesota 2007Post-transfusion mortality among recipients of ABO-compatible but non-identical plasmaPathogen-reduction methods: advantages and limitsCost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision MakingErythropoietic therapy: Cost efficiency and reimbursementReview article: the prothrombin time test as a measure of bleeding risk and prognosis in liver diseaseCurrent Risks of Transfusion-Transmitted Agents: A ReviewPathogen Inactivation: The Definitive Safeguard for the Blood SupplyBlood Substitutes: Basic Principles and Practical AspectsStrategies for testing blood donors for West Nile virusCoagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current managementScreening the United States Blood Supply for West Nile Virus: A Question of Blood, Dollars, and SenseCorrection: Meeting Transfusion Safety Expectations 4 October 2005Volume 143, Issue 7Page: 537-538KeywordsBloodBlood banksBlood transfusionHIVHematologic testsLungsNucleic acidsSafetyWest Nile virus ePublished: 4 October 2005 Issue Published: 4 October 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...